Trial Profile
A Randomized Evaluation of Antiretroviral Therapy Alone or With Delayed Chemotherapy Versus Antiretroviral Therapy With Immediate Adjunctive Chemotherapy for Treatment of Limited Stage AIDS-KS in Resource-Limited Settings (REACT-KS) AMC 067
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate (Primary) ; Etoposide (Primary)
- Indications HIV-1 infections; Kaposi's sarcoma
- Focus Therapeutic Use
- Acronyms REACT-KS
- 01 Nov 2019 Status changed from active, no longer recruiting to completed.
- 30 Jul 2018 Planned End Date changed from 1 Dec 2019 to 21 Sep 2019.
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science